newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Reported positive topline results from the Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, meeting the primary endpoint with significant reductions in PANSS total scores & improvements in cognitive function
  • Advanced ML-007C-MA for schizophrenia into a planned Phase 3 ZEPHYR-2 trial with expected topline results in 2028 following an End-of-Phase 2 meeting with the FDA
  • Continued enrollment in the Phase 2 VISTA trial for ML-007C-MA in Alzheimer's Disease Psychosis (ADP), with top-line results expected in the second half of 2027
  • Reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, showing clinically meaningful improvements in irritability among adolescents despite missing the primary social communication endpoint
  • Prioritized resources on ML-007C-MA advancement while pausing investment in preclinical programs & foregoing advancement of those programs into clinical development
  • Announced a $150 million private placement in August 2026 to support ML-007C-MA development & working capital
  • Ended the quarter with $351.3 million in cash, cash equivalents, & investments, extending the cash runway through 2028 including through projected readouts for VISTA & ZEPHYR-2
  • Reported second quarter 2026 R&D expenses of $53.4 million, G&A expenses of $10.1 million, & a net loss of $60.2 million